ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Seattle, WA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Seattle, WA, USA:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib

Phase 1, Phase 2

Kura Oncology

Seattle, Washington, United States and 51 other locations

in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...

Active, not recruiting
Leukemia
Drug: Dasatinib

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Seattle, Washington, United States and 173 other locations

single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML).The dose escalation (Part A) of the study will explor...

Enrolling
Leukemia, Myeloid
Drug: CC-96191

Phase 1

Celgene
Celgene

Seattle, Washington, United States and 13 other locations

treating measurable residual disease in patients with acute myeloid leukemia. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzu...

Enrolling
Acute Myeloid Leukemia
Other: Quality-of-Life Assessment
Drug: Gemtuzumab Ozogamicin

Phase 2

University of Washington
University of Washington

Seattle, Washington, United States

allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...

Active, not recruiting
Acute Myelogenous Leukemia
Leukemia, Acute Myeloid
Drug: Conventional Care
Drug: Iomab-B

Phase 3

Actinium Pharmaceuticals
Actinium Pharmaceuticals

Seattle, Washington, United States and 23 other locations

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....

Enrolling
Acute Mixed-Phenotype Leukemia
Acute Lymphoblastic Leukemia
Drug: BMF-500

Phase 1

Biomea Fusion

Seattle, Washington, United States and 22 other locations

This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (C...

Active, not recruiting
Chronic Lymphocytic Leukemia
Prolymphocytic Leukemia
Drug: Acalabrutinib

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Seattle, Washington, United States and 11 other locations

with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Seattle, Washington, United States and 108 other locations

This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Uproleselan
Drug: Placebo

Phase 3

GlycoMimetics

Seattle, Washington, United States and 69 other locations

works in treating medically less-fit patients with acute myeloid leukemia or other high-grade myeloid neoplasms. Drugs used in chemotherapy,...

Enrolling
Acute Myeloid Leukemia
Myeloid Neoplasm
Biological: Recombinant Granulocyte Colony-Stimulating Factor
Drug: Liposome-encapsulated Daunorubicin-Cytarabine

Phase 2

Fred Hutchinson Cancer Center (FHCC)
Fred Hutchinson Cancer Center (FHCC)

Seattle, Washington, United States

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems